WO2009118658A2 - Endoplasmic reticulum targeting liposomes - Google Patents

Endoplasmic reticulum targeting liposomes Download PDF

Info

Publication number
WO2009118658A2
WO2009118658A2 PCT/IB2009/005547 IB2009005547W WO2009118658A2 WO 2009118658 A2 WO2009118658 A2 WO 2009118658A2 IB 2009005547 W IB2009005547 W IB 2009005547W WO 2009118658 A2 WO2009118658 A2 WO 2009118658A2
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
lipids
lipid particle
liposomes
virus
Prior art date
Application number
PCT/IB2009/005547
Other languages
English (en)
French (fr)
Other versions
WO2009118658A3 (en
Inventor
Stephanie Pollock
Raymond Allen Dwek
Nicole Zitzmann
Original Assignee
University Of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Oxford filed Critical University Of Oxford
Priority to CA2719567A priority Critical patent/CA2719567A1/en
Priority to CN2009801186452A priority patent/CN102046151A/zh
Priority to JP2011501322A priority patent/JP2011518124A/ja
Priority to EP09726097A priority patent/EP2282723A2/en
Publication of WO2009118658A2 publication Critical patent/WO2009118658A2/en
Publication of WO2009118658A3 publication Critical patent/WO2009118658A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/IB2009/005547 2008-03-26 2009-03-25 Endoplasmic reticulum targeting liposomes WO2009118658A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2719567A CA2719567A1 (en) 2008-03-26 2009-03-25 Endoplasmic reticulum targeting liposomes
CN2009801186452A CN102046151A (zh) 2008-03-26 2009-03-25 靶向内质网的脂质体
JP2011501322A JP2011518124A (ja) 2008-03-26 2009-03-25 小胞体ターゲッティングリポソーム
EP09726097A EP2282723A2 (en) 2008-03-26 2009-03-25 Endoplasmic reticulum targeting liposomes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3963808P 2008-03-26 2008-03-26
US61/039,638 2008-03-26

Publications (2)

Publication Number Publication Date
WO2009118658A2 true WO2009118658A2 (en) 2009-10-01
WO2009118658A3 WO2009118658A3 (en) 2010-03-11

Family

ID=41114387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/005547 WO2009118658A2 (en) 2008-03-26 2009-03-25 Endoplasmic reticulum targeting liposomes

Country Status (7)

Country Link
US (2) US20090252785A1 (US20090252785A1-20091008-C00001.png)
EP (1) EP2282723A2 (US20090252785A1-20091008-C00001.png)
JP (1) JP2011518124A (US20090252785A1-20091008-C00001.png)
KR (1) KR20100127842A (US20090252785A1-20091008-C00001.png)
CN (1) CN102046151A (US20090252785A1-20091008-C00001.png)
CA (1) CA2719567A1 (US20090252785A1-20091008-C00001.png)
WO (1) WO2009118658A2 (US20090252785A1-20091008-C00001.png)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015815A2 (en) * 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010109330A3 (en) * 2009-03-27 2011-11-10 University Of Oxford Cholesterol level lowering liposomes
WO2015053910A2 (en) 2013-09-16 2015-04-16 Glycomine Llc Pharmaceutical preparation of carbohydrates for therapeutic use
CN113603763A (zh) * 2019-12-30 2021-11-05 中国科学院生物物理研究所 一种脂肪体及其在检测atgl酶活性中的应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
RU2453536C2 (ru) * 2007-10-22 2012-06-20 Оркид Рисерч Лабораториз Лимитед Ингибиторы гистондезацетилазы
CN102655746B (zh) * 2009-02-23 2016-08-03 联合治疗公司 亚氨基糖以及治疗病毒性疾病的方法
KR101787434B1 (ko) * 2009-02-24 2017-11-15 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
WO2010143970A2 (en) * 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylcholine
US8426445B2 (en) * 2009-06-12 2013-04-23 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
KR101459530B1 (ko) * 2009-09-04 2014-11-07 유나이티드 세러퓨틱스 코오포레이션 폭스바이러스 감염의 치료 방법
JP5653438B2 (ja) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
WO2011028779A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
CA2783405A1 (en) * 2009-12-07 2011-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation
US8846081B2 (en) 2010-08-13 2014-09-30 Rhode Island Board Of Governors For Higher Education Liposome compositions and methods of use thereof
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
EP3046558B1 (en) 2013-09-16 2019-08-14 Emergent Virology LLC Deoxynojirimycin derivatives and methods of their using
WO2015060504A1 (ko) * 2013-10-22 2015-04-30 한국과학기술원 세포막결합성 리포좀에 의한 세포변형을 통하여 세포막성 수포에 약물을 포접하는 방법 및 이를 이용한 약물의 전달 방법
BR112017008898B1 (pt) 2014-11-05 2022-11-29 Emergent Virology Llc Compostos de iminoaçúcares, suas composições farmacêuticas e usos dos mesmos para tratar doenças virais
WO2017192599A1 (en) * 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011781A1 (en) * 1989-04-04 1990-10-18 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
WO2002024162A1 (en) * 2000-09-18 2002-03-28 Vasogen Ireland Limited Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
WO2003024422A1 (en) * 2001-09-18 2003-03-27 Vasogen Ireland Limited Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
WO2005063213A1 (en) * 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
WO2007127439A2 (en) * 2006-04-28 2007-11-08 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
WO2009011007A2 (en) * 2007-07-16 2009-01-22 Universita Degli Studi Di Roma 'tor Vergata' Asymmetric liposomes and uses in medical field thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2834122A1 (de) * 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2853573A1 (de) * 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US4690486A (en) * 1985-04-29 1987-09-01 Texas Instruments Incorporated Four position interlacing apparatus
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
DE3650377T2 (de) * 1985-12-23 1996-02-22 Hutchinson Fred Cancer Res Regulierung der retroviralen replikation, infektion und pathogenese.
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
DE3611841A1 (de) * 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
IT1208751B (it) * 1986-06-30 1989-07-10 Fidia Farmaceutici Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali
US4792558A (en) * 1987-05-29 1988-12-20 Merrell Dow Pharmaceuticals Inc. Castanospermine for inhibiting tumor metastasis
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US4861892A (en) * 1988-02-12 1989-08-29 G. D. Searle & Co. Method for synthesis of deoxymannojirimycin
US5837709A (en) * 1988-08-10 1998-11-17 The Australian National University Use of castanospermine as an anti-inflammatory and immunosupressant agent
US5691346A (en) * 1988-08-10 1997-11-25 The Australian National University Castanospermine as an anti-inflammatory and immunosuppressant agent
US4910310A (en) * 1988-10-03 1990-03-20 G. D. Searle & Co. Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US5310745A (en) * 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US4952585A (en) * 1988-12-15 1990-08-28 Merrell Dow Pharmaceuticals Inc. Castanospermine esters in the inhibition of tumor metastasis
US4894388A (en) * 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
US5011929A (en) * 1989-05-15 1991-04-30 Monsanto Company Synthesis of mannojirimycin derivatives
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5214050A (en) * 1989-10-17 1993-05-25 Merrell Dow Pharmaceuticals Inc. Esters of castanospermine in the treatment of cerebral malaria
US4996329A (en) * 1989-10-20 1991-02-26 Monsanto Company Derivatives of 1,4-dideoxy-1,4-imino-D-mannitol and a process for their preparation
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
US5401645A (en) * 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
ATE223204T1 (de) * 1992-04-10 2002-09-15 Hisamitsu Pharmaceutical Co Liposomenzusammensetzung
US5286877A (en) * 1993-02-01 1994-02-15 G. D. Searle & Co. Synthesis of 1,4-dideoxy-1,4-imino-L-arabinitol
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5750648A (en) * 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5709865A (en) * 1994-11-10 1998-01-20 Biostar Inc. Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53)
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
MX9708008A (es) * 1995-04-19 1998-03-31 Polymun Scient Immunbio Forsch Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6041252A (en) * 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5908867A (en) * 1996-07-18 1999-06-01 Henry; James P. Reduction of hair growth
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
AU753336B2 (en) * 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) * 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
CA2312423A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
US6809083B1 (en) * 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US20020151683A1 (en) * 1998-03-30 2002-10-17 Mogam Biotechnology Research Institute Liposomes comprising peptide antigens derived from X protein of hepatitis B virus
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6515028B1 (en) * 1999-02-12 2003-02-04 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
EP1165080A2 (en) * 1999-02-12 2002-01-02 G.D. SEARLE & CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
US6656912B2 (en) * 2000-01-20 2003-12-02 Washington University In St. Louis Methods to treat α1-antitrypsin deficiency
US6828306B2 (en) * 2000-07-31 2004-12-07 Ottawa Heart Institute Research Corporation Charged lipid compositions and methods for their use
WO2002085358A2 (en) * 2001-04-20 2002-10-31 Vion Pharmaceuticals, Inc. Antiviral agents and methods of treating viral infections
AU2002348971A1 (en) * 2001-10-12 2003-04-28 Stefana M. Petrescu Ph-sensitive liposomes for targeted drug delivery
WO2003037265A2 (en) * 2001-10-30 2003-05-08 Thomas Jefferson University Method of treating viral infections
JP4555569B2 (ja) * 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
US20060093577A1 (en) * 2004-10-06 2006-05-04 Migenix Inc. Combination anti-viral compositions and methods of use
AU2006206187B2 (en) * 2005-01-24 2011-03-10 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
US20060194835A1 (en) * 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
US7875289B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US8975280B2 (en) * 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011781A1 (en) * 1989-04-04 1990-10-18 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
WO2002024162A1 (en) * 2000-09-18 2002-03-28 Vasogen Ireland Limited Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
WO2003024422A1 (en) * 2001-09-18 2003-03-27 Vasogen Ireland Limited Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
WO2005063213A1 (en) * 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
WO2007127439A2 (en) * 2006-04-28 2007-11-08 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
WO2009011007A2 (en) * 2007-07-16 2009-01-22 Universita Degli Studi Di Roma 'tor Vergata' Asymmetric liposomes and uses in medical field thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015815A2 (en) * 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010015815A3 (en) * 2008-08-05 2010-08-26 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010109330A3 (en) * 2009-03-27 2011-11-10 University Of Oxford Cholesterol level lowering liposomes
CN102427804A (zh) * 2009-03-27 2012-04-25 牛津大学之校长及学者 降低胆固醇水平的脂质体
WO2015053910A2 (en) 2013-09-16 2015-04-16 Glycomine Llc Pharmaceutical preparation of carbohydrates for therapeutic use
US10449149B2 (en) 2013-09-16 2019-10-22 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use
US11045419B2 (en) 2013-09-16 2021-06-29 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use
EP3954360A2 (en) 2013-09-16 2022-02-16 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use
CN113603763A (zh) * 2019-12-30 2021-11-05 中国科学院生物物理研究所 一种脂肪体及其在检测atgl酶活性中的应用
CN113603763B (zh) * 2019-12-30 2023-09-01 中国科学院生物物理研究所 一种脂肪体及其在检测atgl酶活性中的应用

Also Published As

Publication number Publication date
WO2009118658A3 (en) 2010-03-11
JP2011518124A (ja) 2011-06-23
KR20100127842A (ko) 2010-12-06
US20090252785A1 (en) 2009-10-08
US20120237592A1 (en) 2012-09-20
CN102046151A (zh) 2011-05-04
CA2719567A1 (en) 2009-10-01
EP2282723A2 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
US20090252785A1 (en) Endoplasmic reticulum targeting liposomes
Pollock et al. Uptake and trafficking of liposomes to the endoplasmic reticulum
EP2399587A1 (en) Liposome treatment of viral infections
Colley et al. Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation
Yu et al. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma
Dalpiaz et al. Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system
US8703744B2 (en) Cholesterol level lowering liposomes
CN102292069B (zh) 囊泡制剂
JP2009512716A (ja) Ｈｉｖ−１キャプシド構築の低分子阻害剤
Szebeni et al. Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes
JPWO2009096487A1 (ja) オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
Yang et al. Nanotechnology advances in pathogen-and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control
CN106798923B (zh) 功能靶向性载体材料二硬脂酰磷脂酰乙醇胺-聚乙二醇-聚乙烯亚胺化合物及其修饰的脂质体
Xiao et al. Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo
Du et al. Dimeric artesunate glycerophosphocholine conjugate nano-assemblies as slow-release antimalarials to overcome Kelch 13 mutant artemisinin resistance
Marwah et al. Functionally engineered ‘hepato-liposomes’: Combating liver-stage malaria in a single prophylactic dose
JP5817053B2 (ja) 腫瘍特異性を有するリポソーム
JP2014028761A (ja) マクロファージ機能抑制及び／又は癌細胞増殖抑制
Weil Advanced molecular tweezers as broad-spectrum antivirals
Mehan et al. Ligand Decorated Primaquine Loaded Nanocarriers for Liver Targeting for Triggered Anti-Malarial Activity
Hadidi Probing the Cellular Delivery Capabilities of Modified Aminoglycosides
Crommelin et al. Targeting with IgG and immunoliposomes to circulating cells: the ‘target cell dragging’concept
Weissig et al. 11 Mitochondria-Targeted Drug Delivery
IT201800006278A1 (it) Bionanofenretinide nuova formulazione antitumorale

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980118645.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2011501322

Country of ref document: JP

Ref document number: 2719567

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7117/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009726097

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107023507

Country of ref document: KR

Kind code of ref document: A